# MEPSGEN Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mepsgen-co

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.mepsgen.com/
- Total disclosed funding: $17M
- Latest round: Series C (Nov 19, 2024)
- Investors on record: 8

## About

Based in South Korea, MEPSGEN Co., Ltd. is a biotechnology company specializing in advanced drug development solutions, focusing on enhancing the drug discovery process for pharmaceutical and biotechnology sectors.Founded in 2020, MEPSGEN Co., Ltd. operates from Seoul, South Korea, focusing on innovative platforms for drug development. The company has raised a total of KRW 20.7 billion through Series C funding, which will support its growth initiatives. The CEO and founder, YongTae Kim, has a background in biotechnology, contributing to the company's strategic vision.MEPSGEN specializes in advanced drug development platforms, offering innovative solutions through its core product lines: ProMEPS™, MEPS-X series, and NanoCalibur™. ProMEPS™ provides a robust framework for pharmaceutical companies, focusing on enhancing the efficiency and effectiveness of drug discovery processes. The MEPS-X series is designed to optimize the microfluidic handling of compounds, significantly reducing development time and costs. NanoCalibur™ targets micro and nano-scale applications, catering to the pharmaceutical industry's need for precision in drug formulation and delivery systems. These products serve a diverse clientele, including pharmaceutical and biotechnology companies, research institutions, and laboratories across North America, Europe, and Asia-Pacific, aiming to address critical challenges in drug development and enhance therapeutic outcomes.MEPSGEN generates revenue primarily through direct sales and partnerships with pharmaceutical companies and research institutions. Transactions typically involve the sale of its flagship products, including ProMEPS™ and NanoCalibur™, structured as one-time purchases or as part of subscription-based service agreements for ongoing support and updates. The pricing structure reflects the specialized nature of these products, with costs aligned to the value provided in accelerating drug development timelines and improving efficacy. MEPSGEN’s client engagements often entail customized solutions tailored to specific research needs, fostering long-term relationships within the B2B sector. This business model allows MEPSGEN to maintain a steady revenue stream while delivering high-value solutions to its partners in the pharmaceutical domain.In November 2024, MEPSGEN Co., Ltd. raised KRW 20.7 billion in Series C funding from new investors including Yuanta Investment, KB Securities, Solidus Investment, E&Investment, and Live Cell Instrument, with returning investors KDB Bank and SBI Investment Korea also participating. The funding will be utilized to support the launch of new products designed to further enhance drug development capabilities. MEPSGEN plans to expand into additional markets across Europe and North America by 2025, leveraging its innovative platforms to address the evolving needs of the pharmaceutical sector.

## Funding rounds

- Series C, Nov 19, 2024, $15M — SBI Investment Korea, Korea Development Bank, Yuanta Investment, E&Investment, Solidus Investment, KB Securities, Live Cell Instrument
- Series A, Sep 7, 2020, $2.5M — Korea Investment Partners

## Investors

- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A
- SBI Investment Korea (https://capitalatlas.ai/funds/sbi-investment-korea) — Series C
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series C
- Yuanta Investment (https://capitalatlas.ai/funds/yuanta-investment) — Series C
- E&Investment (https://capitalatlas.ai/funds/e-investment) — Series C
- Solidus Investment (https://capitalatlas.ai/funds/solidus-investment) — Series C
- KB Securities (https://capitalatlas.ai/funds/kb-securities) — Series C
- Live Cell Instrument — Series C